started · updated
Montelukast asthma medication shows potential in inhibiting tumor growth
A study published in the journal Nature Cancer suggests that Montelukast, a common asthma medication also known as Singulair, may have potential in treating various types of cancer. Researchers at Northwestern University, led by Bin Zhang, investigated how the drug affects tumor growth and the immune system.
The research focused on how tumors reprogram white blood cells to evade immunotherapy. By using mouse models and human tissue, the team discovered that Montelukast acts as an antagonist to the CysLTR1 receptor. While this receptor is typically associated with asthma and inflammation, blocking it appears to inhibit the proliferation of cancer cells.
This approach falls under drug repurposing, which utilizes existing, safety-tested medications for new therapeutic uses. The findings are particularly relevant for aggressive and immunotherapy-resistant cancers, such as triple-negative breast cancer.
Entities
Bin Zhang · Montelukast · Nature Cancer · Northwestern University
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] A research team led by Bin Zhang at Northwestern University published findings in the journal Nature Cancer. www.op-online.de · www.merkur.de
- [● 3 SOURCES] The asthma medication Montelukast (Singulair) may help treat various types of cancer. www.op-online.de · www.merkur.de
- [● 3 SOURCES] The study investigated how tumors reprogram white blood cells to evade immunotherapy. www.op-online.de · www.merkur.de
- [● 3 SOURCES] Montelukast inhibits the CysLTR1 molecule, which is involved in asthma and inflammation. www.op-online.de · www.merkur.de
- [● 3 SOURCES] Experiments were conducted using mouse models and human tissue. www.op-online.de · www.merkur.de
- [● 3 SOURCES] The research aims to find treatments for cancers resistant to immunotherapy, such as triple-negative breast cancer. www.op-online.de · www.merkur.de